Industry Today Logo

Published Thu, Mar 14th 2019

Hormone Replacement Therapy Market Adopts Innovation to Stay Competitive Forecast 2026

Increasing prevalence of hypogonadism in adult men worldwide is expected to drive growth of the hormone replacement therapy market.

Posted via Industry Today. Follow us on Twitter @IndustryToday


Hormone replacement therapy is used when human body is not able to produce enough hormones. It is used for the treatment for menopause, hypothyroidism, male hypogonadism, and growth hormone deficiency conditions.

Rising incidences of hormonal imbalance disorders and increasing geriatric and neonatal population suffering from these diseases are expected to boost growth of the market. According to the statistics provided by the American Congress of Obstetricians and Gynecologists, around 6,000 women reach menopause on a daily basis in U.S.

Market Dynamics

Increasing number of people suffering from hypogonadism and rising adoption of testosterone products in various economies is expected to propel overall growth of the market. According to the data published in the European Association of Urology Journal: 2017, testosterone prescription trends in the U.S. exhibited an increase between 1.8- and 4-fold over the last two decades (1997 - 2017). Moreover, from 2000 to 2011, there was a 4.3-fold increase in testosterone testing when compared to a 3.7-fold increase in prescriptions.

Rising number of generic versions of hormone replacement therapies by various manufacturers will drive growth of the market in terms of volume and value. For instance, Teva Pharmaceutical Industries Ltd. launched the generic Axiron1 (testosterone) topical solution CIII, 30 mg/1.5 mL, in the U.S. on August 18, 2017 to treat adult males who have low or no testosterone due to certain medical conditions. This solution was supplied in a metered dose pump with an underarm applicator.

Hormone Replacement Therapy Market - Regional Insights

On the basis of region, the global hormone replacement therapy market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the global hormone replacement therapy market, owing to continuous launch of various generic products for hormone replacement therapies by manufacturers.

Furthermore, Europe is expected to be the second largest contributor to the hormone replacement therapy market, in terms of revenue and is expected to gain significant traction in the near future. This is owing to launch of new drugs and therapies to combat secondary hyperparathyroidism and presence of significant population suffering from the disease in this region.

Get Exclusive Sample Report at: https://www.coherentmarketinsights.com/insight/request-sample/2079

Increasing prevalence of various chronic conditions are expected to drive growth of the hormone replacement therapy market

Increasing prevalence of hypogonadism in adult men worldwide is expected to drive growth of the hormone replacement therapy market.

According to the European Association of Urology: 2016 report, in middle-aged men, the incidence of hypogonadism varies from 2.1% to 12.8%. The incidence of low testosterone and symptoms of hypogonadism in men aged 40-79 varies form 2.1% to 5.7%, in Europe.

Ease in access and government support for research and development activities is expected to aid in growth of the hormone replacement therapy market. Financial help by NGOs such as the National Gaucher Society help patients receive enzyme replacement therapy that are costly.

Hormone Replacement Therapy Market - Competitive Landscape

Manufacturers are focusing on developing generic versions of various drugs for the treatment of certain disorders that are highly prevalent in women such as hypothyroidism. For instance, Teva Pharmaceutical Industries Ltd. launched generic version of Vagifem (estradiol vaginal inserts), 10 mcg in the U.S. on 24, July 2017. Estradiol vaginal inserts are an estrogen indicated for the treatment of atrophic vaginitis due to menopause.

Moreover, on December 29, 2017, Mylan N.V. got the U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Estradiol Vaginal Cream USP, 0.01% and thus, the company launched this drug in the U.S. This cream is the first generic version of Allergan's Estrace Cream, indicated for the treatment of vulvar and vaginal atrophy.

Key players operating in the global hormone replacement therapy market include Novartis AG, Abbott Laboratories, Mylan N.V., Merck KgaA, Bayer AG, Pfizer Inc., Novo Nordisk A/S, QuatRx Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Amgen, Inc., and Eli Lilly and Company.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
 


Contact information

Pareesh Phulkar
Coherent Market Insights
1001 4th Ave,
#3200
Seattle
98154
2067016702
https://www.coherentmarketinsights.com/

Visit www.industrytoday.co.uk to publish and distribute news from your Industry. Optimised press releases appear in Google News. Connect with us via the social networks Twitter, Facebook, LinkedIn, Google+ and Pinterest